Background SJS-TENs pathogenesis is not completely explained and its immunological symptoms are similar to graft versus host disease so; it is possible to say that SJS-TEN is a disorder of the cell-mediated immunity. We report a first case of patient with intracranial tumors who developed a cutaneous adverse drug reaction during lansoprazole and prophylactic anticonvulsants treatment.
Methods
Our patient is a 64 year-old female, who had glioma and had been on post-op anticonvulsants therapy. On the 3rd day after she had an operation, lansoprazole was added to the therapy. After the first lansoprazole dose erythematous dusky red macules were occured in extremities and trunk and on the following day confluent purpuric lesions tended to run together in 95% of the whole body including scalp and, oral and genital mucosa. Nikolsky's Sign was positive on the skin. Body temparature was 38.4°C with heart rate of 146beats/min. GlascowComaScale was E1M1e, pupillary light reflex was 2/2+/+. SCORTEN was calculated as 5 and her biopsy resulted as TEN.
Results
As a treatment, firstly fluid and electrolyte homeostasis and skin lesions were maintained. For daily nutritional requirements total parenteral nutrition was supplied. Human albumin and IVIG in dose of 400mg/kg were usedand pulse steroid therapy. She was discharged from the hospital on the 23rd day and followed in the clinical immunology unit after 2 months.
Conclusions
On six day intensive care unit serum STRAIL level was 302 pg/mL and in blister fluid soluble TRAIL level was 603 pg/mL. Two months after dischange serum soluble TRAIL level was 546 pg/mL. We found that the amounts of soluble TRAIL were higher in TEN blister fluids than in serum at the same time and after two months. TRAIL and TWEAK were secreted by CD1a+ and CD14+ cells present in the blister fluids we studied.This result suggest that TRAIL could also be a mediators of keratinocyte cell death in SJS-TEN.
